MA28004A1 - Traitement du sevrage de la dependance - Google Patents

Traitement du sevrage de la dependance

Info

Publication number
MA28004A1
MA28004A1 MA28830A MA28830A MA28004A1 MA 28004 A1 MA28004 A1 MA 28004A1 MA 28830 A MA28830 A MA 28830A MA 28830 A MA28830 A MA 28830A MA 28004 A1 MA28004 A1 MA 28004A1
Authority
MA
Morocco
Prior art keywords
buprenorphine
dosage form
dosage
days
dosing period
Prior art date
Application number
MA28830A
Other languages
English (en)
Inventor
Bruce E Reidenberg
Daniel A Spyker
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MA28004A1 publication Critical patent/MA28004A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B2101/00—Type of solid waste
    • B09B2101/65—Medical waste
    • B09B2101/68—Transdermal patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Materials Engineering (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Drying Of Semiconductors (AREA)
  • Cephalosporin Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)

Abstract

On décrit des régimes de dosage de buprénorphine pour traiter le syndrome du sevrage et de l'abstinence chez une patiente enceinte dépendant d'une drogue ou tolérant un opioïde. Le procédé comporte le traitement du syndrome de sevrage et de l'abstinence de la patiente par l'administration transdermique d'une quantité efficace de buprénorphine pour réduire les syndromes de sevrage. On peut par exemple administrer au patient une première forme de dosage transdermique contenant de la buprénorphine pour une première période de dosage qui n'est pas plus longue que 5 jours; une seconde forme de dosage transdermique contenant de la buprénorphine pour une première période de dosage qui n'est pas plus longue que 5 jours , où la seconde forme de dosage comprend le même dosage de buprénorphine que , ou un plus grand dosage de buprénorphine que ladite première forme de dosage; et une troisième forme de dosage transdermique contenant de la buprénorphine pour une troisième période de dosage pour au moins 2 jours, où la troisième forme de dosage comprend un plus grand dosage de buprénorphine que la seconde forme de dosage.
MA28830A 2003-07-25 2006-02-23 Traitement du sevrage de la dependance MA28004A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49040703P 2003-07-25 2003-07-25

Publications (1)

Publication Number Publication Date
MA28004A1 true MA28004A1 (fr) 2006-07-03

Family

ID=34115390

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28830A MA28004A1 (fr) 2003-07-25 2006-02-23 Traitement du sevrage de la dependance

Country Status (28)

Country Link
US (1) US8637073B2 (fr)
EP (1) EP1646328B1 (fr)
JP (2) JP2007500134A (fr)
KR (1) KR100829492B1 (fr)
CN (1) CN1829482B (fr)
AT (1) ATE375149T1 (fr)
AU (1) AU2004261182B2 (fr)
BR (1) BRPI0412931A (fr)
CA (1) CA2530005C (fr)
CY (1) CY1107262T1 (fr)
DE (1) DE602004009449T2 (fr)
DK (1) DK1646328T3 (fr)
EA (1) EA009921B1 (fr)
ES (1) ES2295929T3 (fr)
GE (1) GEP20125454B (fr)
HR (1) HRP20070476T3 (fr)
IL (1) IL173346A (fr)
IS (1) IS2630B (fr)
MA (1) MA28004A1 (fr)
MX (1) MXPA06000991A (fr)
NO (1) NO333189B1 (fr)
NZ (1) NZ545505A (fr)
PL (1) PL1646328T3 (fr)
PT (1) PT1646328E (fr)
SI (1) SI1646328T1 (fr)
UA (1) UA81056C2 (fr)
WO (1) WO2005011579A2 (fr)
ZA (1) ZA200510069B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (fr) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Posologie transdermique de buprénorphine pour l'analgésie
DK1572167T3 (da) 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
ATE375149T1 (de) 2003-07-25 2007-10-15 Euro Celtique Sa Behandlung von entzug
CN101316623A (zh) * 2005-09-30 2008-12-03 Tti优而美株式会社 系统输送活性剂的离子电渗方法和装置
WO2009106831A2 (fr) * 2008-02-28 2009-09-03 Syntropharma Limited Composition pharmaceutique
US8163731B2 (en) * 2008-08-20 2012-04-24 Rhodes Technologies Method and dosage regimens for eliminating a chemical substance in blood
US9879204B2 (en) 2010-03-17 2018-01-30 Method Products, Pbc Liquid cleaning compositions with lower freezing point
US11236351B2 (en) 2010-05-17 2022-02-01 Dow Agrosciences Llc Production of DHA and other LC PUFAs in plants
TW201307553A (zh) 2011-07-26 2013-02-16 Dow Agrosciences Llc 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術
KR102082529B1 (ko) 2012-04-17 2020-02-27 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
DK3400066T3 (da) * 2016-01-08 2021-10-18 Ohio State Innovation Foundation Behandlinger og forebyggelse af neonatalt opioidt abstinenssyndrom
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CN107648234A (zh) * 2017-08-04 2018-02-02 中国人民解放军第二军医大学 一种治疗吗啡成瘾戒断症状的阿片类药物组合物
IL277801B2 (en) * 2018-04-09 2025-06-01 Katana Pharmaceuticals Inc Oxytocin compositions and methods of use
WO2021043771A1 (fr) * 2019-09-02 2021-03-11 Camurus Ab Formulations et procédés de traitement
CA3207013A1 (fr) 2021-02-01 2022-08-04 Xinhua Li Composes de sequestration pour le traitement d'un trouble de l'usage d'une substance et leurs utilisations
WO2024036337A2 (fr) * 2022-08-12 2024-02-15 Bio Ventures, Llc Buprénorphine deutérée en tant qu'agent protecteur pour des sujets fœtaux contre une exposition aux opioïdes agonistes complets

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
DE3939376C1 (fr) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (fr) * 1989-12-12 1991-06-19 Warner-Lambert Company Système d'administration transdermique pour le traitement de la cocainomanie et de l'héroinomanie
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
JPH06183956A (ja) 1992-12-24 1994-07-05 Teisan Seiyaku Kk 安定な貼付用の製剤
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
EP0821957A3 (fr) 1996-08-01 1998-04-22 Eli Lilly And Company Utilisation de la 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tétrahydro-1-méthylpyridine (xanoméline) pour traiter l'abus de drogues
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
AU2002348135A1 (en) * 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
AU2003224742A1 (en) 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
DK1572167T3 (da) 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
WO2004103317A2 (fr) 2003-05-15 2004-12-02 Euro-Celtique S.A. Regime posologique pour le traitement de la diarrhee par administration de buprenorphine par voie transdermique
ATE375149T1 (de) 2003-07-25 2007-10-15 Euro Celtique Sa Behandlung von entzug

Also Published As

Publication number Publication date
AU2004261182A1 (en) 2005-02-10
KR100829492B1 (ko) 2008-05-19
NO333189B1 (no) 2013-03-25
US8637073B2 (en) 2014-01-28
AU2004261182B2 (en) 2008-05-15
EA200600200A1 (ru) 2006-06-30
US20060240085A1 (en) 2006-10-26
WO2005011579A2 (fr) 2005-02-10
PL1646328T3 (pl) 2008-03-31
BRPI0412931A (pt) 2006-09-26
CY1107262T1 (el) 2012-11-21
IS8187A (is) 2005-12-19
IL173346A (en) 2011-02-28
ATE375149T1 (de) 2007-10-15
ZA200510069B (en) 2006-10-25
CN1829482B (zh) 2012-10-10
PT1646328E (pt) 2007-10-24
SI1646328T1 (sl) 2008-02-29
EA009921B1 (ru) 2008-04-28
JP2011252020A (ja) 2011-12-15
EP1646328A4 (fr) 2006-08-30
JP2007500134A (ja) 2007-01-11
IS2630B (is) 2010-06-15
UA81056C2 (en) 2007-11-26
CA2530005A1 (fr) 2005-02-10
DE602004009449D1 (de) 2007-11-22
CA2530005C (fr) 2011-09-27
NO20060913L (no) 2006-04-21
MXPA06000991A (es) 2006-04-11
DK1646328T3 (da) 2008-02-04
HRP20070476T3 (en) 2008-01-31
NZ545505A (en) 2010-02-26
EP1646328A2 (fr) 2006-04-19
ES2295929T3 (es) 2008-04-16
GEP20125454B (en) 2012-03-26
CN1829482A (zh) 2006-09-06
KR20060037400A (ko) 2006-05-03
WO2005011579A3 (fr) 2005-06-09
DE602004009449T2 (de) 2008-07-24
EP1646328B1 (fr) 2007-10-10
IL173346A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
ES2224430T3 (es) Noribogaina en el tratamiento del dolor y de la toxicomania.
ATE302003T1 (de) Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
RU2008138381A (ru) Режимы дозирования адреналина
JP2007500134A5 (fr)
JP2004537500A5 (fr)
ATE405272T1 (de) Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
IL318374A (en) Methods of administering nalbuphine
UA81689C2 (ru) Способ предоперационного лечения послеоперационной боли бупренорфином
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
Naber et al. Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
UA132403U (uk) Спосіб лікування хронічних панкреатитів та реабілітації післяопераційних хворих
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
RU2004114005A (ru) Способ лечения алкогольных болезней печени